Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04567420
Title DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer (DARE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Criterium, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Palbociclib

Age Groups: adult | child | senior
Covered Countries USA

Additional content available in CKB BOOST